{"id":70664,"date":"2026-05-12T08:56:17","date_gmt":"2026-05-12T08:56:17","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70664"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mots-c","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/mots-c\/","title":{"rendered":"MOTS-c"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 MOTS-c\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>MOTS-c<\/strong> (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino-acid mitochondrially-encoded signaling peptide first identified in 2015. In published preclinical studies it acts as an exercise-mimetic and metabolic regulator by activating the AMPK pathway, restoring insulin sensitivity, and modulating nuclear gene expression in response to mitochondrial stress. Supplied in 10\u00a0mg to 40\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1627580-64-6<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2174.62 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR\u300116\u30a2\u30df\u30ce\u9178\uff1b\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a212S rRNA\u907a\u4f1d\u5b50\u306b\u30b3\u30fc\u30c9\u3055\u308c\u3066\u3044\u308b)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f7f\u7528\u6642\u5728\u5eab\u306f2\uff5e8\u2103\uff08\u51b7\u8535\uff09\u306b\u4fdd\u7ba1\u3002\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306b\u306f\u221220\u2103\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u2103\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u6642\u9593\u4f7f\u7528\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>MOTS-c\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>MOTS-c<\/strong> \uff0812S rRNA-c\u306e\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u30aa\u30fc\u30d7\u30f3\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30d5\u30ec\u30fc\u30e0\uff09\u306f\u3001Lee\u3089\u306b\u3088\u3063\u3066\u6700\u521d\u306b\u540c\u5b9a\u3055\u308c\u305f16\u30a2\u30df\u30ce\u9178\u306e\u30da\u30d7\u30c1\u30c9\u3067\u3001 <em>Cell Metabolism<\/em> (2015) as a member of the newly recognised class of mitochondrially-derived peptides (MDPs). Unlike every other peptide in the studies catalog \u2014 which are encoded by nuclear DNA and synthesised in the cytoplasm \u2014 MOTS-c is encoded within the mitochondrial 12S rRNA gene and translated by mitochondrial ribosomes. This unusual biological origin makes it a direct intracellular signal of mitochondrial state, and the most-cited member of a peptide class that includes humanin and the SHLP family. The peptide sequence is MRWQEMGYIFYPRKLR, molecular weight approximately 2,175\u00a0Da, empirical formula C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub>. \u5185\u56e0\u6027MOTS-c\u306f\u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u3084\u9178\u5316\u30b9\u30c8\u30ec\u30b9\u4e0b\u3067\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u304b\u3089\u6838\u3078\u79fb\u884c\u3057\u3001\u8449\u9178\u56de\u8def\/\u30e1\u30c1\u30aa\u30cb\u30f3\u4ee3\u8b1d\u907a\u4f1d\u5b50\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u8abf\u7bc0\u3057\u307e\u3059\u3002\u3053\u308c\u306f\u6838\u30b3\u30fc\u30c9\u30da\u30d7\u30c1\u30c9\u306b\u306f\u985e\u3092\u898b\u306a\u3044\u30e1\u30ab\u30cb\u30ba\u30e0\u3067\u3059\u3002MOTS-c\u306f\u9ad8\u7d14\u5ea6\u306e\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u3068\u3057\u3066\u4f9b\u7d66\u3055\u308c\u3001\u9759\u83cc\u6c34\u3067\u518d\u6eb6\u89e3\u3057\u3066\u4f7f\u7528\u3055\u308c\u307e\u3059\u3002\u305d\u3057\u3066\u3001 <strong>for clinical studies use only<\/strong>. For related metabolic and longevity peptides, see our full <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a>. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 AMPK\u3001\u30b0\u30eb\u30b3\u30fc\u30b9\u4ee3\u8b1d\u3001\u304a\u3088\u3073\u6838\u79fb\u884c<\/h2>\n<p>MOTS-c\u3092\u5f93\u6765\u306e\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u3068\u5dee\u5225\u5316\u3059\u308b\u306e\u306f\u3001\u305d\u306e <strong>3\u3064\u306e\u4f5c\u7528\u6a5f\u5e8f<\/strong> that spans the mitochondrion, the cytoplasm, and the nucleus \u2014 each contributing to the observed metabolic phenotype in published studies:<\/p>\n<ul>\n<li><strong>AMPK\u7d4c\u8def\u306e\u6d3b\u6027\u5316<\/strong> \u2014 MOTS-c\u306f\u3001\u7d30\u80de\u5185AMP:ATP\u6bd4\u306e\u4e0a\u6607\u3068\u8449\u9178\u56de\u8def\u4f9d\u5b58\u6027\u30e1\u30ab\u30cb\u30ba\u30e0\u3092\u901a\u3058\u3066\u3001\u7d30\u80de\u306e\u4e3b\u8981\u306a\u30a8\u30cd\u30eb\u30ae\u30fc\u30bb\u30f3\u30b5\u30fc\u3067\u3042\u308bAMP\u6d3b\u6027\u5316\u30d7\u30ed\u30c6\u30a4\u30f3\u30ad\u30ca\u30fc\u30bc\uff08AMPK\uff09\u3092\u6d3b\u6027\u5316\u3057\u307e\u3059\u3002AMPK\u306e\u6d3b\u6027\u5316\u306f\u7d30\u80de\u4ee3\u8b1d\u3092\u7570\u5316\u65b9\u5411\u3078\u30b7\u30d5\u30c8\u3055\u305b\u307e\u3059\uff1aGLUT4\u30c8\u30e9\u30f3\u30b9\u30ed\u30b1\u30fc\u30b7\u30e7\u30f3\u3092\u4ecb\u3057\u305f\u30b0\u30eb\u30b3\u30fc\u30b9\u53d6\u308a\u8fbc\u307f\u306e\u5897\u52a0\u3001\u8102\u80aa\u9178\u9178\u5316\u3001PGC-1\u03b1\u3092\u4ecb\u3057\u305f\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u751f\u5408\u6210\u3001\u305d\u3057\u3066\u30aa\u30fc\u30c8\u30d5\u30a1\u30b8\u30fc\u3067\u3059\u3002\u3053\u308c\u306f\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u3084\u904b\u52d5\u304c\u6a19\u7684\u3068\u3059\u308b\u306e\u3068\u540c\u3058\u7d4c\u8def\u3067\u3042\u308a\u3001\u767a\u8868\u3055\u308c\u305f\u6587\u732e\u3067MOTS-c\u304c\u300c\u904b\u52d5\u6a21\u5023\u30da\u30d7\u30c1\u30c9\u300d\u3068\u79f0\u3055\u308c\u308b\u6240\u4ee5\u3067\u3059\u3002<\/li>\n<li><strong>\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3068\u30b0\u30eb\u30b3\u30fc\u30b9\u51e6\u7406<\/strong> \u2014 In high-fat-diet rodent models, MOTS-c administration restores insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. The effect is independent of body-weight change in some studies designs, suggesting a direct insulin-sensitising mechanism rather than secondary to weight loss. MOTS-c-treated obese mice show normalised oral glucose tolerance and improved euglycaemic-clamp parameters in published studies.<\/li>\n<li><strong>\u6838\u79fb\u884c\u3068\u9069\u5fdc\u7684\u907a\u4f1d\u5b50\u767a\u73fe<\/strong> \u2014 \u4ee3\u8b1d\u30b9\u30c8\u30ec\u30b9\u3084\u9178\u5316\u30b9\u30c8\u30ec\u30b9\u4e0b\u3067\u306f\u3001MOTS-c\u306f\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u304b\u3089\u6838\u3078\u79fb\u884c\u3057\u3001\u6297\u9178\u5316\u5fdc\u7b54\uff08NRF2\uff09\u3001\u8449\u9178-\u30e1\u30c1\u30aa\u30cb\u30f3\u56de\u8def\u3001\u304a\u3088\u3073\u9069\u5fdc\u7684\u4ee3\u8b1d\u907a\u4f1d\u5b50\u3092\u4e2d\u5fc3\u3068\u3057\u305f\u8ee2\u5199\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u5171\u8abf\u7bc0\u3057\u307e\u3059\u3002\u3053\u306e\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u304b\u3089\u6838\u3078\u306e\u9006\u884c\u6027\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u306f\u3001\u7d30\u80de\u5185\u533a\u753b\u9593\u30b3\u30df\u30e5\u30cb\u30b1\u30fc\u30b7\u30e7\u30f3\u306e\u30da\u30d7\u30c1\u30c9\u30ec\u30d9\u30eb\u3067\u306e\u6700\u521d\u306e\u4f8b\u306e\u4e00\u3064\u3067\u3042\u308a\u3001\u76f4\u63a5\u7684\u306aAMPK\u6d3b\u6027\u5316\u3092\u8d85\u3048\u305fMOTS-c\u306e\u5e83\u7bc4\u306a\u52b9\u679c\u306e\u57fa\u76e4\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/li>\n<\/ul>\n<p>The biological appeal of MOTS-c in metabolic support is the convergence of these three mechanisms onto pathways already known to mediate the benefits of exercise and caloric restriction. Because endogenous MOTS-c declines markedly with age in human serum (~50% reduction across adult lifespan in published cohorts), the peptide has become a frequent target in aging and longevity studies as well as in metabolic syndrome. <\/p>\n<h2>Published Evidence<\/h2>\n<p>MOTS-c is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Metabolic syndrome and obesity studies<\/strong> \u2014 insulin sensitivity, glucose tolerance, body composition in high-fat-diet rodent models; benchmark peptide for AMPK-axis intervention studies (Lee et al., Cell Metabolism 2015; Reynolds et al., Front Physiol 2021)<\/li>\n<li><strong>2\u578b\u7cd6\u5c3f\u75c5\u306e\u524d\u81e8\u5e8a\u30e2\u30c7\u30eb<\/strong> \u2014 db\/db\u3001ZDF\u3001\u304a\u3088\u3073\u30b9\u30c8\u30ec\u30d7\u30c8\u30be\u30c8\u30b7\u30f3\u8a98\u767a\u7cd6\u5c3f\u75c5\u30e2\u30c7\u30eb\uff1b\u809d\u81d3\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3001\u03b2\u7d30\u80de\u6a5f\u80fd\u3001HbA1c\u4ee3\u66ff\u6307\u6a19\u306b\u53ca\u307c\u3059\u5f71\u97ff<\/li>\n<li><strong>\u904b\u52d5\u80fd\u529b\u3068\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u751f\u5408\u6210<\/strong> \u2014 \u30c8\u30ec\u30c3\u30c9\u30df\u30eb\u6301\u4e45\u529b\u3001VO<sub>2<\/sub>max surrogates, PGC-1\u03b1 expression, mitochondrial DNA copy number in skeletal muscle studies<\/li>\n<li><strong>Aging and longevity studies<\/strong> \u2014 lifespan extension models, age-related insulin resistance, sarcopenia; MOTS-c serum levels decline with age, making it a candidate replacement peptide in geroscience studies<\/li>\n<li><strong>\u5fc3\u8840\u7ba1\u304a\u3088\u3073\u814e\u4fdd\u8b77<\/strong> \u2014 ischaemia-reperfusion injury, oxidative stress markers, mitochondrial dysfunction in cardiac and renal tissue study models<\/li>\n<li><strong>Bone health studies<\/strong> \u2014 \u9aa8\u82bd\u7d30\u80de\u5206\u5316\u3001\u9aa8\u5bc6\u5ea6\u3001\u52a0\u9f62\u6027\u9aa8\u7c97\u9b06\u75c7\u30e2\u30c7\u30eb<\/li>\n<li><strong>Comparative mitochondrial peptide studies<\/strong> \u2014 \u4ed6\u306e\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u6a19\u7684\u30da\u30d7\u30c1\u30c9\u3068\u306e\u30d9\u30f3\u30c1\u30de\u30fc\u30af\uff08\u4f8b\uff1a <a href=\"https:\/\/medsbase.com\/ja\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a>. \u65b9\u6cd5\u8ad6\u7684\u306a\u6bd4\u8f03\u306b\u3064\u3044\u3066\u306f\u4e0b\u8a18\u306e\u6bd4\u8f03\u30bb\u30af\u30b7\u30e7\u30f3\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/li>\n<\/ul>\n<p>MOTS-c\u304c\u4ee3\u8b1d\u304a\u3088\u3073\u9577\u5bff\u30da\u30d7\u30c1\u30c9\u306e\u5168\u4f53\u50cf\u306e\u4e2d\u3067\u3069\u306e\u3088\u3046\u306b\u4f4d\u7f6e\u3065\u3051\u3089\u308c\u308b\u304b\u306b\u3064\u3044\u3066\u3001\u3088\u308a\u5e83\u3044\u6587\u8108\u306b\u3064\u3044\u3066\u306f\u3001 <a href=\"https:\/\/medsbase.com\/ja\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> \u5178\u578b\u7684\u306a\u30ab\u30eb\u30b8\u30aa\u30ea\u30d4\u30f3\u6a19\u7684\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u30da\u30d7\u30c1\u30c9\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/epitalon\/\">Epitalon<\/a> for telomere\/longevity studies, and <a href=\"https:\/\/medsbase.com\/ja\/nad\/\">NAD+<\/a> for NAD-axis metabolic support. Browse the full <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks MOTS-c in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, short-cycle protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u4e2d\u91cf\u30d0\u30eb\u30af\u30d0\u30a4\u30a2\u30eb\u3001\u7528\u91cf\u3042\u305f\u308a\u306e\u518d\u6eb6\u89e3\u6db2\u91cf\u3092\u4f4e\u6e1b<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle protocols, longevity studies, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials yield greater per-vial dose flexibility and lower per-mg cost; the trade-off is that reconstituted solution must be used within 30 days, so multi-month protocols benefit from larger vials only when the per-week dose is correspondingly high. <\/p>\n<h2>MOTS-c \u5bfe SS-31\uff08\u30a8\u30e9\u30df\u30d7\u30ec\u30c1\u30c9\uff09\u2014 \u6bd4\u8f03\u30dd\u30a4\u30f3\u30c8<\/h2>\n<p>MOTS-c\u3068 <a href=\"https:\/\/medsbase.com\/ja\/ss-31-elamipretide\/\">SS-31<\/a> are the two most-cited mitochondrially-targeted peptides in current studies. They are mechanistically distinct and complementary, not redundant: MOTS-c is a signalling peptide that activates AMPK and nuclear-encoded adaptive programmes, while SS-31 is a structural peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. Users often pair them in mitochondrial-dysfunction models for this reason. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">SS-31 (Elamipretide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16\u30a2\u30df\u30ce\u9178<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u30a2\u30df\u30ce\u9178\uff08\u30c6\u30c8\u30e9\u30da\u30d7\u30c1\u30c9\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7531\u6765<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2DNA\u306b\u30b3\u30fc\u30c9\u3055\u308c\u308b\uff0812S rRNA\u907a\u4f1d\u5b50\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5408\u6210Szeto-Schiller\u30da\u30d7\u30c1\u30c9<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e3b\u306a\u4f5c\u7528\u6a5f\u5e8f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">AMPK\u6d3b\u6027\u5316\u3001\u6838\u5185\u907a\u4f1d\u5b50\u767a\u73fe<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30ab\u30eb\u30b8\u30aa\u30ea\u30d4\u30f3\u7d50\u5408\u3001ETC\u5b89\u5b9a\u5316<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7d30\u80de\u6a19\u7684<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2 \u2192 \u7d30\u80de\u8cea \u2192 \u6838<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u5185\u819c\u306e\u307f<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e00\u822c\u7684\u306a\u7528\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5\uff5e15mg\u3001\u90311\uff5e3\u56de<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\uff5e5mg\u3001\u6bce\u65e5<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3001\u904b\u52d5\u80fd\u529b\u3001\u8001\u5316<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5fc3\u865a\u8840\u3001\u814e\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u6a5f\u80fd\u4e0d\u5168<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30b9\u30bf\u30c3\u30ad\u30f3\u30b0<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frequently co-administered with SS-31 in mitochondrial studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">MOTS-c\u3068\u4f75\u7528\u3055\u308c\u308b\u3053\u3068\u304c\u591a\u3044<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides act on different layers of mitochondrial biology \u2014 MOTS-c regulates metabolic transcription, SS-31 stabilises membrane architecture \u2014 so they address non-overlapping studies questions. For metabolic\/insulin sensitivity, MOTS-c is the default first choice. For cardiac, renal, or ischaemia-reperfusion mitochondrial protection, SS-31 is the canonical comparator. <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u3001\u77ed\u671f\u4f7f\u7528\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u3067\u306f\u3001-20\u00b0C\u3067\u51cd\u7d50\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5MOTS-c\u306f\u3001\u51b7\u8535\u3067\u6700\u957724\u30f6\u6708\u3001-20\u00b0C\u3067\u6700\u957736\u30f6\u6708\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u6ce8\u5c04\u7528\u9759\u83cc\u6c34\u3092\u30da\u30d7\u30c1\u30c9\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u6ce8\u5165\u3057\u3066\u304f\u3060\u3055\u3044\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u300210 mg\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u30012.0 mL\u306e\u9759\u83cc\u6c34\u30675 mg\/mL\u306e\u4f7f\u7528\u6fc3\u5ea6\u304c\u5f97\u3089\u308c\u3001U-100\u30a4\u30f3\u30b9\u30ea\u30f3\u30b7\u30ea\u30f3\u30b8\u306e10\u76ee\u76db\u308a\u304c500 mcg\u306b\u76f8\u5f53\u3057\u307e\u3059\u3002\u9759\u304b\u306b\u3086\u3063\u304f\u308a\u3068\u6df7\u305c\u3001\u2014 \u884c\u3046 <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u3063\u3066\u2014 \u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30672\uff5e5\u5206\u9593\u9759\u7f6e\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u306a\u3051\u308c\u3070\u306a\u308a\u307e\u305b\u3093\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because MOTS-c is typically dosed 1\u20133 times weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20133 weeks of dosing depending on the target dose and frequency. <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is MOTS-c used for in studies?<\/h3>\n<p>MOTS-c is used in studies investigating insulin sensitivity, type 2 diabetes models, exercise capacity, mitochondrial biogenesis, aging and longevity, cardiovascular ischaemia-reperfusion injury, renal mitochondrial dysfunction, and bone health. It is the most-cited mitochondrially-encoded signalling peptide in the published literature and serves as a benchmark for AMPK-axis interventions. MOTS-c is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied here strictly for clinical studies use only. <\/p>\n<h3>MOTS-c\u306fSS-31\uff08\u30a8\u30e9\u30df\u30d7\u30ec\u30c1\u30c9\uff09\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>MOTS-c is a 16-amino-acid signalling peptide encoded by mitochondrial DNA that activates AMPK and regulates nuclear gene expression. SS-31 is a 4-amino-acid synthetic Szeto-Schiller peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. The two address different layers of mitochondrial biology \u2014 MOTS-c at the metabolic-transcription level, SS-31 at the membrane-architecture level \u2014 and are frequently co-administered in mitochondrial-dysfunction studies. <\/p>\n<h3>What is the typical MOTS-c dose?<\/h3>\n<p>\u516c\u8868\u3055\u308c\u3066\u3044\u308b\u524d\u81e8\u5e8a\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f\u3001\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3044\u3066\u3001\u901a\u5e381\u56de\u3042\u305f\u308a5\uff5e15 mg\u3092\u3001\u90311\uff5e3\u56de\u30014\uff5e12\u9031\u9593\u306e\u30b5\u30a4\u30af\u30eb\u3067\u6295\u4e0e\u3057\u307e\u3059\u300210 mg\u306e\u30d0\u30a4\u30a2\u30eb\u30922.0 mL\u306e\u9759\u83cc\u6c34\u3067\u6eb6\u89e3\u3059\u308b\u30685 mg\/mL\u306e\u6fc3\u5ea6\u306b\u306a\u308a\u3001U-100\u30b7\u30ea\u30f3\u30b8\u306e10\u76ee\u76db\u308a\u304c500 mcg\u306b\u76f8\u5f53\u3057\u307e\u3059\u3002 <\/p>\n<h3>MOTS-c\u306fFDA\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. MOTS-c is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. <\/p>\n<h3>MOTS-c\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f-20\u00b0C\u3067\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u5f8c\u306e\u6eb6\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306b\u3088\u308a\u30da\u30d7\u30c1\u30c9\u304c\u5206\u89e3\u3055\u308c\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u5149\u3092\u907f\u3051\u3066\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h3>MOTS-c\u306e\u6eb6\u89e3\u65b9\u6cd5\u3092\u6559\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/h3>\n<p>\u4e0a\u8a18\u306e\u518d\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u6ce8\u5c04\u7528\u9759\u83cc\u6c34\u3092\u30d0\u30a4\u30a2\u30eb\u306e\u5185\u58c1\u306b\u6cbf\u3063\u3066\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u5f53\u3066\u306a\u3044\u3088\u3046\u306b\uff09\u52a0\u3048\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30672\uff5e5\u5206\u9593\u7f6e\u304d\u307e\u3059\u3002 <strong>\u3057\u307e\u305b\u3093<\/strong> \u30d0\u30a4\u30a2\u30eb\u3092\u632f\u3089\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6b63\u3057\u304f\u518d\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u900f\u660e\u3067\u7121\u8272\u3067\u3059\u300210 mg\u30d0\u30a4\u30a2\u30eb\u306b2.0 mL\u306e\u6eb6\u89e3\u6db2\u3092\u52a0\u3048\u305f\u5834\u5408\u3001\u4f5c\u696d\u6fc3\u5ea6\u306f5 mg\/mL\u3067\u3059\u3002 <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries MOTS-c in 10\u00a0mg, 20\u00a0mg, and 40\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>MOTS-c\u304c\u300c\u904b\u52d5\u6a21\u5023\u300d\u30da\u30d7\u30c1\u30c9\u3068\u547c\u3070\u308c\u308b\u7406\u7531\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>The term derives from MOTS-c&#8217;s activation of AMPK and downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis \u2014 the same intracellular pathway responsible for many of the metabolic adaptations to exercise. In published studies, MOTS-c administration replicates several phenotypes of exercise training in sedentary animals: improved insulin sensitivity, increased treadmill endurance, and elevated PGC-1\u03b1 expression in skeletal muscle. The metaphor is widely used in geroscience and metabolic-syndrome literature. <\/p>\n<h3>Can MOTS-c and SS-31 be stacked in studies?<\/h3>\n<p>Yes. MOTS-c and SS-31 act on different layers of mitochondrial biology and are frequently co-administered in preclinical mitochondrial-dysfunction studies. MOTS-c regulates metabolic transcription via AMPK; SS-31 stabilises the inner-membrane lipid environment. Their mechanisms are complementary rather than overlapping, which makes the combination useful in study models of multi-axis mitochondrial decline. <\/p>\n<h3>Does MOTS-c cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses in rodent models, with no consistent off-target signals and good tolerability across 4\u201312 week dosing cycles. MOTS-c is structurally an endogenous human peptide, which reduces the risk of antibody-mediated reactions seen with engineered analogs. Long-term human safety data are not available because human trials are still in early stages. <\/p>\n<h3>MOTS-c\u306e\u534a\u6e1b\u671f\u306f\u3069\u306e\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>In preclinical studies, MOTS-c has an estimated plasma half-life of approximately 3\u20134 hours following subcutaneous administration. The relatively short systemic half-life is offset by intracellular accumulation and the peptide&#8217;s role as an intracellular signalling molecule rather than a circulating hormone \u2014 effects persist beyond the plasma clearance window in study models. <\/p>\n<h3>\u306a\u305c\u52a0\u9f62\u3068\u3068\u3082\u306b\u5185\u56e0\u6027MOTS-c\u306f\u6e1b\u5c11\u3059\u308b\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>Published cohort data show roughly a 50% decline in human serum MOTS-c levels between young and aged adults. The mechanism is not fully understood but is thought to relate to age-associated mitochondrial DNA mutations, declining mitochondrial transcription, and reduced biosynthesis of mitochondrially-encoded peptides in general. The age-related decline is one reason MOTS-c has attracted strong interest in longevity and geroscience studies. <\/p>\n<h3>How long does MOTS-c take to show effects in preclinical studies?<\/h3>\n<p>AMPK\u30ea\u30f3\u9178\u5316\u304a\u3088\u3073\u30b0\u30eb\u30b3\u30fc\u30b9\u53d6\u308a\u8fbc\u307f\u306b\u5bfe\u3059\u308b\u6025\u6027\u52b9\u679c\u306f\u3001\u6295\u4e0e\u5f8c\u6570\u6642\u9593\u4ee5\u5185\u306b\u691c\u51fa\u53ef\u80fd\u3067\u3059\u3002\u9ad8\u8102\u80aa\u98df\u3092\u4e0e\u3048\u305f\u3052\u3063\u6b6f\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u304a\u3088\u3073\u4f53\u7d44\u6210\u3078\u306e\u5f71\u97ff\u306f\u3001\u901a\u5e382\uff5e4\u9031\u9593\u306e\u5b9a\u671f\u7684\u306a\u6295\u4e0e\u5f8c\u306b\u7d71\u8a08\u7684\u306b\u6709\u610f\u306b\u306a\u308a\u307e\u3059\u3002\u904b\u52d5\u80fd\u529b\u306e\u6539\u5584\uff08\u30c8\u30ec\u30c3\u30c9\u30df\u30eb\u6301\u4e45\u529b\u3001VO<sub>2<\/sub>max surrogates) accrue over 4\u20138 weeks of continuous dosing. <\/p>\n<h3>MOTS-c\u3092\u56fd\u969b\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>\u306f\u3044\u3002MedsBase\u306f\u3001\u5c02\u7528\u306e\u30da\u30d7\u30c1\u30c9\u767a\u9001\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u304b\u3089MOTS-c\u3092\u5168\u4e16\u754c\u914d\u9001\u3057\u3066\u3044\u307e\u3059\u3002\u30da\u30d7\u30c1\u30c9\u306e\u307f\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u793e\u306e\u5358\u72ec\u30da\u30d7\u30c1\u30c9\u767a\u9001\u30b5\u30fc\u30d3\u30b9\u306e\u5bfe\u8c61\u3068\u306a\u308a\u307e\u3059\u3002\u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u6e29\u5ea6\u7ba1\u7406\u3055\u308c\u305f\u68b1\u5305\u3067\u8ffd\u8de1\u4ed8\u304d\u3067\u767a\u9001\u3055\u308c\u3001\u5f53\u793e\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Mitochondrial, and Longevity Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 \u30ab\u30eb\u30b8\u30aa\u30ea\u30d4\u30f3\u7d50\u5408\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u30c6\u30c8\u30e9\u30da\u30d7\u30c1\u30c9 \u2014 \u6a19\u6e96\u7684\u306a\u5185\u819c\u5b89\u5b9a\u5316\u5264<\/li>\n<li><a href=\"\/ja\/nad\/\"><strong>NAD+<\/strong><\/a> \u2014 Nicotinamide adenine dinucleotide \u2014 sirtuin\/longevity-axis metabolic support<\/li>\n<li><a href=\"\/ja\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 telomerase activation and longevity studies<\/li>\n<li><a href=\"\/ja\/semaglutide\/\"><strong>\u30bb\u30de\u30b0\u30eb\u30c1\u30c9<\/strong><\/a> \u2014 Long-acting GLP-1 agonist \u2014 glycaemic and body-weight studies<\/li>\n<li><a href=\"\/ja\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u6a19\u7684\u30da\u30d7\u30c1\u30c9\u3092\u6bd4\u8f03\u3059\u308b<\/strong><\/p>\n<p style=\"margin: 0;\">\u3088\u308a\u5e83\u7bc4\u306a <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a> \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u304a\u3088\u3073\u4ee3\u8b1d\u30da\u30d7\u30c1\u30c9\u7528\uff08\u4ee5\u4e0b\u3092\u542b\u3080\uff09 <a href=\"https:\/\/medsbase.com\/ja\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-targeted membrane studies, <a href=\"https:\/\/medsbase.com\/ja\/nad\/\">NAD+<\/a> for sirtuin-axis longevity studies, and <a href=\"https:\/\/medsbase.com\/ja\/epitalon\/\">Epitalon<\/a> for telomere-axis longevity studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u306b\u30b3\u30fc\u30c9\u3055\u308c\u305f\u30b7\u30b0\u30ca\u30eb\u30da\u30d7\u30c1\u30c9<br \/>\n\u2705 AMPK\u4ee3\u8b1d\u7d4c\u8def\u3092\u6d3b\u6027\u5316<br \/>\n\u2705 \u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3092\u30b5\u30dd\u30fc\u30c8<br \/>\n\u2705 \u524d\u81e8\u5e8a\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u904b\u52d5\u6a21\u5023\u5316\u5408\u7269<br \/>\n\u2705 Longevity &amp; geroscience compound<\/p>\n<p><strong>MOTS-c<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":70967,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6272,5441],"class_list":["post-70664","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mots-c","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70967"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70664"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70664"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70664"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}